Jeffrey Keats

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu et al. · Cancer Cell · 2009 · 1.2K citations · Full text

Hematological Malignancy, Tumor Biology, Chronic Myeloid Leukemia +9

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Wei‐Sheng Huang, Shuangying Liu, Dong Zou et al. · Journal of Medicinal Chemistry · 2016 · 392 citations · Full text

Drug Target, Anaplastic Lymphoma Kinase, Tumor Biology +18

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML

Thomas O’Hare, Roy M. Pollock, Eric P. Stoffregen et al. · Blood · 2004 · 198 citations · Full text

AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes

Justin M. Summy, José G. Treviño, Donald P. Lesslie et al. · Molecular Cancer Therapeutics · 2005 · 79 citations

Bone-Targeted 2,6,9-Trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases

Yihan Wang, Chester A. Metcalf, William C. Shakespeare et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 51 citations · Full text

Medicinal Chemistry, Sclerostin, Bone-targeted 2,6,9-Trisubstituted Purines +10